European court decisions on SPCs gives drug combinations more protection
This article was originally published in SRA
The Court of Justice of the European Union has delivered its judgement on two "seminal" cases involving pharmaceutical supplementary protection certificates1. The rulings "will have immediate and far-reaching consequences not only in relation to the broad SPC protection that might now be granted by patent offices in Europe, but also in connection with the scope and validity of SPCs already granted,” according to the UK law firm, Potter Clarkson2, which acted for Georgetown University et al in one of the two cases under consideration. The party in the other case was Medeva.
You may also be interested in...
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.
Innovators warn against slashing incentives and argue a lack of a common definition of unmet need is a stumbling block to proposals.